What is the recommended treatment for an unresectable myxopapillary ependymoma?

Treatment of Unresectable Myxopapillary Ependymoma

For unresectable myxopapillary ependymoma, postoperative radiotherapy with doses ≥50 Gy is the recommended treatment. 1

Primary Treatment Approach

The EANO (European Association of Neuro-Oncology) guidelines from 2018 provide clear, evidence-based recommendations for this specific scenario. When gross total resection (GTR) is not feasible for myxopapillary ependymoma (MPE), the standard of care is:

• Radiotherapy with doses ≥50 Gy (Class II evidence, Level B recommendation) 1

This recommendation is based on compelling outcome data showing that high-dose radiotherapy significantly improves disease control:

• 10-year progression-free survival increases from <40% to 70% with radiotherapy doses ≥50 Gy compared to surgery alone 1
• The treatment is well-tolerated without substantial late toxicity 1
• Local control is significantly improved with high-dose radiotherapy 1

Why Surgery Cannot Be Achieved

MPE presents unique surgical challenges that make complete resection difficult:

• Irregular tumor shape with myxoid matrix production, particularly in the filum terminale 1
• Intimate contact with surrounding nerve roots and neural structures 1
• Risk of capsular violation during surgery, which strongly correlates with recurrence 1
• Risk of postoperative neurological disability when attempting aggressive resection 1

Essential Staging Before Treatment

Before initiating radiotherapy, complete disease staging is mandatory:

• Craniospinal MRI with contrast (not earlier than 2-3 weeks post-surgery) 1
• CSF cytology to detect dissemination 1
• This is critical because CSF dissemination occurs in approximately 9-20% of MPE patients 1, 2, 3

Radiotherapy Technical Details

The optimal radiotherapy approach includes:

• Minimum dose: 50 Gy to the tumor bed 1
• Local field radiotherapy for localized disease 1
• Consider craniospinal irradiation if CSF dissemination or drop metastases are present 3

Recent data from a 2023 cohort study of 72 patients confirms that adjuvant radiotherapy significantly improves progression-free survival in patients with preoperative drop metastasis (p = 0.039) 3, supporting the guideline recommendations.

Long-Term Surveillance Strategy

Lifelong MRI surveillance is mandatory because:

• MPE has a high risk of late recurrence even after apparently successful treatment 1
• Recurrences can be asymptomatic 1
• The 10-year overall survival exceeds 90%, making long-term follow-up feasible and worthwhile 1
• Enhanced MRI should be performed at regular intervals indefinitely 1

Treatment at Recurrence

If disease recurs despite initial radiotherapy, the EANO guidelines recommend considering (in order of preference):

1. Re-operation if technically feasible 1
2. Re-irradiation using fractionated or stereotactic techniques 1
3. Chemotherapy only when local treatment options are exhausted (Class III evidence, Level C recommendation) 1

Critical Prognostic Factors

Understanding these factors helps predict outcomes:

• Younger age (<36 years) is associated with worse prognosis 1
• Presacral location has worse outcomes compared to filum terminale/cauda equina region 1
• Preoperative drop metastasis significantly increases recurrence risk (HR 3.648, p = 0.027) 3
• Tumor involvement of sacrococcygeal region increases recurrence (HR 7.563, p = 0.003) 3

Common Pitfalls to Avoid

• Do not delay radiotherapy in cases of incomplete resection—the evidence clearly shows benefit
• Do not use chemotherapy as first-line adjuvant therapy—it is reserved only for recurrent disease when surgery and radiotherapy are no longer options 1
• Do not perform staging MRI too early—wait at least 2-3 weeks post-surgery to avoid confusing postoperative changes with residual disease 1
• Do not assume low-grade histology means low recurrence risk—MPE was reclassified as WHO grade 2 in 2021 specifically because of its high recurrence probability 3